MedKoo Cat#: 145592 | Name: Letosteine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Letosteine is a mucolytic agent containing two blocked thiol groups. LETOSTEINE may have a therapeutic application in preventing oxidative tissue injury damage induced by the respiratory burst.

Chemical Structure

Letosteine
Letosteine
CAS#53943-88-7

Theoretical Analysis

MedKoo Cat#: 145592

Name: Letosteine

CAS#: 53943-88-7

Chemical Formula: C10H17NO4S2

Exact Mass: 279.0600

Molecular Weight: 279.37

Elemental Analysis: C, 42.99; H, 6.13; N, 5.01; O, 22.91; S, 22.95

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Letosteine; Viscotiol;
IUPAC/Chemical Name
2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)thiazolidine-4-carboxylic acid
InChi Key
IKOCLISPVJZJEA-UHFFFAOYSA-N
InChi Code
1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14)
SMILES Code
CCOC(=O)CSCCC1NC(CS1)C(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 279.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gachon F, Nicolas C, Maurizis JC, Verny M, Chabard JL, Faurie M, Gaillard G. Disposition and metabolism of letosteine in rats. Drug Metab Dispos. 1988 Nov- Dec;16(6):853-7. PMID: 2907465. 2: Donath A, Llull JB, Schifflers MH, Wermeille M. Pharmacokinetic study of 14C-letosteine in man after oral intake and steady-state. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:243-9. PMID: 1820888. 3: Girbino G, Bagnato GF, Giacobbe G. La letosteina nella broncopatia cronica [Letosteine in chronic bronchopathy]. Arch Monaldi. 1983 Jul-Aug;38(4):167-84. Italian. PMID: 6679254. 4: Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial. Pharmazie. 2014 Nov;69(11):842-9. PMID: 25985582. 5: Meroni P, Palmieri G, De Bartolo G, Barcellini W, Albrici A, Froldi M. La letosteina nelle broncopneumopatie ostruttive croniche [Letosteine in chronic obstructive bronchopneumopathy]. Clin Ter. 1983 Apr 30;105(2):109-18. Italian. PMID: 6345052. 6: Liu X, Zheng H, Tang W, Qian Z, Zhu Y, Wang J, Yuan S, Wen X, Cao C, Chen H. Development of a novel LC-MS/MS method for the determination of letosteine in human plasma and its application on pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2554-60. doi: 10.1016/j.jchromb.2011.07.011. Epub 2011 Jul 18. PMID: 21840272. 7: Gressier B, Lebegue N, Brunet C, Luyckx M, Dine T, Cazin M, Cazin JC. Scavenging of reactive oxygen species by letosteine, a molecule with two blocked-SH groups. Comparison with free-SH drugs. Pharm World Sci. 1995 May 26;17(3):76-80. doi: 10.1007/BF01875435. PMID: 7550053. 8: Blaive B, Lapalus P, Lemoigne F. Etude clinique comparée de deux fluidifiants bronchiques: la S-carboxy-méthyl-cystéine et la létostéine [Comparative clinical evaluation of two mucolytic agents: S-carboxy-methyl-cysteine and letosteine (author's transl)]. Sem Hop. 1978 Oct 8-15;54(29-32):983-6. French. PMID: 216094. 9: Cremonini C, Spada E, Cellini F, Cioni R, Giovannini M, Perri G, Priolo U, Fraticelli G, Gusmitta A. I farmaci attivi sul muco nel trattamento di fondo della bronchite cronica. Studio controllato sull'attività della letosteina [Drugs active on mucus in the primary treatment of chronic bronchitis. Controlled study of the activity of letosteine]. Clin Ter. 1986 Jan 31;116(2):121-9. Italian. PMID: 3516537. 10: Nespoli L, Monafo V, Bonetti F, Terracciano L, Savio G. Valutazione clinica dell'attività della letosteina nel trattamento della bronchite acuta febbrile in età pediatrica. Indagine controllata in doppio cieco vs placebo [Clinical evaluation of letosteine activity in the treatment of acute febrile bronchitis in children. Double-blind controlled study versus placebo]. Minerva Pediatr. 1989 Oct;41(10):515-20. Italian. PMID: 2693929. 11: Schroeder K, Fahey T. Should we advise parents to administer over the counter cough medicines for acute cough? Systematic review of randomised controlled trials. Arch Dis Child. 2002 Mar;86(3):170-5. doi: 10.1136/adc.86.3.170. PMID: 11861232; PMCID: PMC1719114. 12: Macquet V, Ficheroulle X, Ta Van P, Peltier M. Un apport nouveau dans le traitement des broncho-pneumopathies chroniques: la létostéine [A new contribution to the treatment of chronic bronchopneumopathies: letosteine]. Lille Med. 1979 Nov;24(9):735-8. French. PMID: 529981. 13: Olivieri D, Del Donno M, Schettini A. Effetto della letosteina sul trasporto muco-ciliare in pazienti affetti da broncopatia cronica [Effect of letosteine on muco-ciliary transport in patients with chronic bronchopathy]. Arch Monaldi. 1983 May-Jun;38(3):105-12. Italian. PMID: 6675560. 14: Morandini G, Finiguerra M, Fraticelli G, Ferraris F, Gallone F. Controllo delle secrezioni bronchiali nelle broncopneumopatie croniche ipersecretive: ruolo della letosteina [The control of bronchial secretions in chronic hypersecretory bronchopneumopathies: the role of letosteine]. Clin Ter. 1986 Feb 15;116(3):179-93. Italian. PMID: 3516541. 15: Kim H, Chang KY, Lee HJ, Han SB, Lee KR. Sensitive determination of erdosteine in human plasma by use of automated 96-well solid-phase extraction and LC-MS/MS. J Pharm Biomed Anal. 2004 Feb 18;34(3):661-9. doi: 10.1016/j.jpba.2003.11.003. PMID: 15127822. 16: Arroll B. Non-antibiotic treatments for upper-respiratory tract infections (common cold). Respir Med. 2005 Dec;99(12):1477-84. doi: 10.1016/j.rmed.2005.09.039. PMID: 16291073. 17: Morandini GC, Perduca M, Finiguerra M, De Martini S, Fraticelli G. Recent advances of knowledge on the mechanism of action of drugs modifying the bronchial secretions. Int J Clin Pharmacol Res. 1986;6(5):415-23. PMID: 3781704. 18: Giudici M, Pascual R, de la Canal L, Pfüller K, Pfüller U, Villalaín J. Interaction of viscotoxins A3 and B with membrane model systems: implications to their mechanism of action. Biophys J. 2003 Aug;85(2):971-81. doi: 10.1016/S0006-3495(03)74536-6. PMID: 12885644; PMCID: PMC1303218.